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Oropharyngitis       
Lemierre syndrome (LS) is a rare, but potentially fatal complication 
of an acute bacterial infection of the head-neck district, characterized by 
local thrombophlebitis and peripheral septic embolization, mainly 
affecting otherwise healthy adolescents and young adults, and typically 
associated with the Gram-negative rod Fusobacterium necrophorum. 
Despite modern antibiotic therapy, 4% of the patients died and 10% had 
disabling long-term sequelae in cases described after 2000 [1]. Little is 
known of the epidemiology and clinical course of LS, and sex differences 
have never been investigated so far. Yet, the pathophysiology of LS may 
involve an interplay of the coagulation cascade with components of 
innate and adaptive immunity [2] known to display sex differences [3], 
particularly in bacterial sepsis [4] and in the age groups most affected by 
LS [5]. Since the condition has a prominent thrombotic component, the 
known sex differences in non-septic venous thromboembolism may also 
apply to it. 
In this retrospective analysis, we analysed sex differences in pre-
sentation, clinical course and impact of prognostic factors in 712 pa-
tients with LS. As previously described [1,6], all cases of patients with LS 
were retrieved that were reported globally between 2000 and 2017, 
without restriction of language or study design, in Medline, Embase, the 
Cochrane Library, the grey literature and the references of retrieved 
articles, and the publishing authors were contacted individually to 
integrate the search. The criteria for LS were: (i) primary head/neck 
bacterial infection; (ii) objectively confirmed head/neck thrombosis or 
peripheral (embolic) septic lesion. Among the cases meeting this broad 
definition of LS, we distinguished those with typical LS, which is 
restricted to cases with oropharyngeal infection and proved isolation of 
Fusobacterium spp. [7]. In all cases, we noted sex, age, typical vs. atypical 
LS, previous medical contacts before diagnosis, bacterial isolation, and 
location of thrombosis and septic lesions at presentation. In cases 
providing data on the clinical course beyond presentation, we recorded 
treatment and clinical outcomes, which included objectively diagnosed 
(i) new/recurrent venous thromboembolism, (ii) new/worsening pe-
ripheral (embolic) septic lesions, (iii) major bleeding, and (iv) death 
from all causes, either in-hospital or within 30 days from diagnosis; and, 
in survivors, clinical sequelae present at discharge, which included 
neurological complications or other functional limitations. 
Sex distribution was assessed using the binomial test for the devia-
tion from a 1:1 ratio. Clinical features at presentation and treatment 
patterns were analysed descriptively, with categorical variables shown 
as frequency (percentage), non-normally distributed continuous vari-
ables as median (interquartile range). Sex differences in clinical out-
comes were compared using the chi-square test; sex differences in the 
association between clinical characteristics of interest and early com-
plications (new/recurrent venous thromboembolism or new peripheral 
septic lesion after diagnosis) were studied using the odds ratios (ORs) 
with 95% CI estimated by multivariable logistic regression in a model 
run for females and males separately, with interaction with sex tested by 
adding the interaction terms of each explanatory variable with sex to a 
single model run on the whole sample. 
A total of 712 patients had information on clinical presentation and 
diagnosis and were used for the analysis of sex distribution and sex 
differences in clinical presentation, while 652 patients, for whom hos-
pital follow-up data up to discharge or beyond was available, were used 
for the analysis of sex differences in the clinical course and in the as-
sociation between variables of interest and early complications. 
Of the 712 patients, 295 (41.4%, 95% CI 37.8%–45.2%) were female 
and 417 (58.6%, 95% CI 54.8%–62.2%) male. Clinical features at pre-
sentation were similar in female and male patients, with females 
marginally younger than males (median: 20, IQR: 16–32 years; vs. me-
dian: 22, IQR: 18–34 years). The most common primary infections were 
oropharyngeal (214/295 of female patients and 306/417 of male pa-
tients), and the most commonly isolated bacterial genus Fusobacterium 
(55.6% of females and 60.2% of males). A total of 235 (79.7%) female 
and 347 (83.2%) male patients had concomitant peripheral (embolic) 
septic lesions, most often pulmonary in both sexes (206, 69.8%; and 300, 
71.9%, respectively). Typical LS was diagnosed in 129 (43.7%) of female 
and 204 (48.9%) of male patients (Table 1). 
In the 652 patients with in-hospital follow-up, we observed no 
evident differences in treatment patterns between sexes. Antibiotics 
were used in almost all patients (98.5% of female and 99.5% of male 
patients) and anticoagulation in 146/272 (53.7%) female and 216/380 
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(56.8%) male patients. Surgical procedures were carried out in 133/272 
(48.9%) female and 204/380 (53.7%) male patients. 
Clinical outcomes were also similar across sexes. Early complica-
tions, including new/recurrent venous thromboembolism or new/ 
worsening peripheral septic lesions, were observed in 40/272 (14.7%) 
female and 53/380 (13.9%) male patients, major bleedings in 6/272 
(2.2%) female and 13/380 (3.4%) male patients. A total of 12/272 
(4.4%) female and 14/380 (3.7%) male patients died. Sequelae at 
discharge were described in 32/260 (12.3%) female and 33/380 (9.0%) 
male survivors (Table 1). 
Multivariable logistic regression with interaction analysis showed 
that in female patients, but not in male patients, positive cultures for 
Fusobacterium spp. were independently associated with early complica-
tions (in female patients: OR 3.06, 95% CI 1.33 to 7.75; in male patients: 
OR 0.88, 95% CI 0.46, 1.73; p value for the interaction sex-isolation of 
Fusobacterium spp.: 0.034; Table 2). No other sex differences were found 
in the association between clinical characteristics at baseline and risk of 
early in-hospital complications, with intracranial involvement at base-
line retaining a strong independent association with in-hospital com-
plications in both sexes (OR 3.00, 95% CI 1.42 to 6.37 in female patients; 
OR 2.06, 95% CI 1.06 to 3.91 in female patients; p value for the inter-
action: 0.430). 
Table 1 
Presentation and clinical course of 712 patients with Lemierre syndrome.  
Presentation and diagnosis Total 
(N = 712) 
Female 
(N = 295) 
Male 
(N = 417) 
Age (years), median (IQR) 21 (17–33) 20 (16–32) 22 (18–34) 
Typical Lemierre syndrome, n (%) 333 (46.8) 129 (43.7) 204 (48.9) 
Previous medical contacts before diagnosis, n (%) 286 (40.2) 115 (39.0) 171 (41.0) 
Primary head and neck infection    
Oropharyngeal, n (%) 520 (73.0) 214 (72.5) 306 (73.4) 
Low respiratory tract, n (%) 330 (46.3) 130 (44.1) 200 (48.0) 
Neck, n (%) 287 (40.3) 117 (39.7) 170 (40.8) 
Other, n (%) 165 (23.2) 67 (22.7) 98 (23.5) 
Bacteria isolated (any), n (%) 583 (81.9) 236 (80.0) 347 (83.2) 
Gram-positive, n (%) 180 (25.3) 71 (24.1) 109 (26.1) 
Gram-negative, n (%) 474 (66.6) 192 (65.1) 282 (67.6) 
Fusobacterium spp., n (%) 415 (58.3) 164 (55.6) 251 (60.2) 
Initial head/neck vein thrombosis, n (%) 597 (83.8) 247 (83.7) 350 (83.9) 
Internal jugular vein thrombosis, n (%) 526 (73.9) 215 (72.9) 311 (74.6) 
Cerebral vein thrombosis, n (%) 143 (20.1) 69 (23.4) 75 (18.0) 
External jugular vein thrombosis, n (%) 43 (6.0) 18 (6.1) 25 (6.0) 
Other, n (%) 116 (16.3) 48 (16.3) 68 (16.3) 
Peripheral septic lesions, n (%) 582 (81.7) 235 (79.7) 347 (83.2) 
Pulmonary, n (%) 506 (71.1) 206 (69.8) 300 (71.9) 
Muscolo-skeletal, n (%) 108 (15.2) 37 (12.5) 71 (17.0) 
Intracranial, n (%) 79 (11.1) 34 (11.5) 45 (10.8) 
Other, n (%) 59 (8.3) 19 (6.4) 40 (9.6)   
Clinical course and outcomes Total 
(N = 652) 
Female 
(N = 272) 
Male 
(N = 380) 
Antibiotic therapy, n (%) 646 (99.7) 268 (98.5) 378 (99.5) 
Penicillins 357 (54.8) 154 (56.6) 203 (53.4) 
Metronidazole 311 (47.7) 124 (45.6) 187 (49.2) 
Cephalosporins 275 (42.2) 119 (43.8) 156 (41.1) 
Other 434 (66.6) 171 (62.9) 263 (69.2) 
Use of anticoagulation, n (%) 362 (55.5) 146 (53.7) 216 (56.8) 
Low-molecular-weight heparin 229 (35.1) 89 (32.7) 140 (36.8) 
Fondaparinux 6 (0.9) 1 (0.4) 5 (1.3) 
Unfractionated heparin 76 (11.7) 33 (12.1) 43 (11.3) 
Direct oral anticoagulants 3 (0.5) 2 (0.7) 1 (0.3) 
Vitamin K antagonists, n (%) 131 (20.1) 56 (20.6) 75 (19.7) 
Length of anticoagulation (days), median (IQR) 84 (21−120) 90 (28–95) 45 (21–90) 
Surgical procedures, n (%) 337 (51.7) 133 (48.9) 204 (53.7) 
Abscess drainage 245 (37.6) 87 (32.0) 158 (41.6) 
Mastoidectomy 40 (6.1) 22 (8.1) 18 (4.7) 
Jugular vein ligation or embolectomy 31 (4.8) 15 (5.5) 16 (4.2) 
Other 114 (17.5) 44 (16.2) 70 (18.4) 
Clinical outcomes    
New/recurrent venous thromboembolism, n (%) 34 (5.2%) 13 (4.8%) 21 (5.5%)* 
New peripheral septic lesion, n (%) 76 (11.7%) 35 (12.9%) 41 (10.5%)* 
Major bleedings, n (%) 19 (2.9%) 6 (2.2%) 13 (3.4%)* 
Death, n (%) 26 (4.0%) 12 (4.4%) 14 (3.7%)*   
Survivors Total 
(N = 626) 
Female 
(N = 260) 
Male 
(N = 366) 
Clinical sequelae, n (%) 65 (10.0%) 32 (12.3%) 33 (9.0%)* 
Typical Lemierre syndrome consisted of acute oropharyngeal infection, isolation of Fusobacterium spp., and either head/neck vein thrombosis or peripheral 
(embolic) septic lesions. New/recurrent venous thromboembolism, new peripheral (embolic) septic lesion, major bleedings, and death were considered as 
Lemierre syndrome complications if they occurred after diagnosis and during hospitalization or within 30 days from the day of admission. IQR = Interquartile 
range. 
* p value >0.05 upon chi-square test. 
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Our results suggest a male predominance in LS less marked than the 
ratio of 2:1 to 3:1 in favour of males repeatedly observed in septicaemia 
due to Fusobacterium necrophorum. This only slight male predominance 
held even when considering cases with Fusobacterium spp. isolation only 
or cases with typical LS only (data not shown). Rather, this finding is 
consistent with a recent nationwide study on exclusively Fusobacterium- 
associated LS which found a sex ratio of 1:1 [8], despite the fact that 
Fusobacterium spp. are not isolated in all cases of LS, and that other 
bacteria have been suggested to be responsible for the same clinical 
syndrome [7]. In this perspective, the slight male majority may reflect a 
moderate reporting bias favouring cases with Fusobacterium spp. isola-
tion, in turn stemming from a detection bias – cases with Fusobacterium 
spp. isolation possibly being more often diagnosed as LS [9]. 
The overall clinical presentation of LS did not display obvious or 
potentially clinically relevant sex differences. In particular, the distri-
bution of cerebral vein thrombosis did not match the known female 
preponderance of 3:1 in this condition [10], suggesting that its patho-
genesis in LS follows a distinct pathway less strongly associated with sex. 
The association of the isolation of Fusobacterium spp. with a worse in- 
hospital prognosis in female patients only is a novel finding that may 
reflect sex-specific differences in the immune reaction to Fusobacterium, 
with the possible implication of more aggressive monitoring or treat-
ment required in case of a positive culture for Fusobacterium in female 
patients. Alternatively, this finding could reflect an intrinsic bias, with 
either Fusobacterium infections in female patients more likely to progress 
to an advanced stage than in males by the time medical attention is 
sought and a diagnosis reached (a form of detection bias) or, among 
advanced cases of LS with Fusobacterium, with this pathogen more likely 
to be isolated in female than male patients because it may have had more 
time to proliferate in the absence of appropriate or timely treatment (a 
form of performance bias). Lastly, selection bias could derive from the 
presence of cases of LS variants of urogenital origin among female pa-
tients who did not report urogenital infections or symptoms, but 
described a recent oropharyngeal infection – a common occurrence in 
the general population – and received a diagnosis of LS [7]. If these 
invasive infections have a worse prognosis than those from an oropha-
ryngeal focus, this subpopulation would bias the association of Fuso-
bacterium spp. with in-hospital complications among female patients in 
the way we observed. This possibility merits attention by specifically 
designed studies, as it would suggest that the finding of Fusobacterium 
spp. should prompt an accurate gynaecological history or examination, 
and calls for further standardization of the diagnostic criteria of LS. 
Our analysis has a number of limitations. First, the associations 
observed do not imply causality and cannot support prediction. Second, 
we analysed cases reported by physicians and researchers; despite the 
inclusion of the grey literature and contact with the authors to include 
unpublished cases, reporting and publication bias cannot be excluded. 
In conclusion, our study confirms a slight imbalance toward males of 
the distribution of LS, shows that no evident or potentially clinically 
relevant sex differences in the presentation or prognosis of LS support 
any sex-specific approach to its management, and suggests a worse in- 
hospital prognosis of female patients with an isolation of Fusobacte-
rium spp. from biological specimens of potential clinical relevance. 
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Table 2 
Multivariable logistic regression analysis of the association between clinical characteristics and early complications, stratified by sex.   
Females, 
OR (95% CI) 
Males, 
OR (95% CI) 
p value for sex interactiona 
Outcome events/patients 40/272 53/380  
Use of anticoagulation 0.55 (0.26–1.14) 0.60 (0.32–1.11)  0.81 
Age (+1 year) 1.01 (0.98–1.03) 1.00 (0.98–1.02)  0.73 
Intracranial involvement at baseline 3.00 (1.42–6.37) 2.06 (1.06–3.91)  0.43 
Peripheral septic lesion at baseline 0.74 (0.30–1.94) 1.65 (0.68–4.67)  0.25 
Isolation of Fusobacterium spp. 3.06 (1.33–7.75) 0.88 (0.46–1.73)  0.03 
Use of anti-Fusobacterium antibiotics 1.19 (0.56–2.47) 1.44 (0.78–2.65)  0.68 
Early complications were new/recurrent venous thromboembolism or new peripheral (embolic) septic lesions objectively diagnosed after the diagnosis of Lemierre 
syndrome and in-hospital or within 30 days from admission. Intracranial involvement at diagnosis was defined as cerebral venous thrombosis or intracranial sup-
puration at diagnosis. Peripheral (embolic) septic lesion at diagnosis was defined as any septic distance suppuration at diagnosis. The use of anticoagulants and of a 
combination of antibiotic therapy specific for Fusobacterium spp. was defined at the time of complication (cases) vs. during hospitalization (controls). OR = odds ratio. 
CI = confidence interval. 
a Tested in a model run on the whole sample and including both main effects and interaction terms with sex for all covariates. 
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